Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

References

• Andreoni M, Bassetti M, Corrao S, De Rosa FG, Esposito V, Falcone M, Grossi P, Pea F, Petrosillo N, Tascini C, Venditti M, Viale P. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 Mar 16:1–10. doi:10.1080/14787210.2021.1894130. Epub ahead of print. 
   Google Scholar
• DunneMW, PuttaguntaS, SprengerCR, RubinoC, Van WartS, BaldassarreJ. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855. doi:10.1128/AAC.04550-1425561338
   PubMed Web of Science ®Google Scholar
• BoucherHW, WilcoxM, TalbotGH, PuttaguntaS, DasAF, DunneMW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. doi:10.1056/NEJMoa131048024897082
   PubMed Web of Science ®Google Scholar
• DunneMW, PuttaguntaS, GiordanoP, KrievinsD, ZelaskyM, BaldassarreJ. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551. doi:10.1093/cid/civ98226611777
   PubMed Web of Science ®Google Scholar
• DoiY. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz83031724043
   PubMed Web of Science ®Google Scholar
• ThomasG, Henao-MartínezAF, Franco-ParedesC, ChastainDB. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56(3):106069. doi:10.1016/j.ijantimicag.2020.10606932603683
   PubMed Web of Science ®Google Scholar
• Herrera-HidalgoL, de AlarcónA, López-CortesLE, et al. Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives. Antibiotics (Basel). 2020;9(10). doi:10.3390/antibiotics9100657
   Web of Science ®Google Scholar
• Durante-MangoniE, GambardellaM, IulaVD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020;56(4):106107. doi:10.1016/j.ijantimicag.2020.10610732721599
   PubMed Web of Science ®Google Scholar
• SpellbergB, LipskyBA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393–407. doi:10.1093/cid/cir84222157324
   PubMed Web of Science ®Google Scholar
• Luque PazD, LakbarI, TattevinP. A review of current treatment strategies for infective endocarditis. Expert Rev Anti Infect Ther. 2021;19(3):297–307. doi:10.1080/14787210.2020.182216532901532
   PubMed Web of Science ®Google Scholar
• MansourO, KellerS, KatzM, TownsendJL. Outpatient parenteral antimicrobial therapy in the time of COVID-19: the urgent need for better insurance coverage. Open Forum Infect Dis. 2020;7(8):ofaa287. doi:10.1093/ofid/ofaa28732832575
   PubMed Web of Science ®Google Scholar
• DashRP, BabuRJ, SrinivasNR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond). 2017;49(7):483–492. doi:10.1080/23744235.2017.129696828264598
   PubMed Web of Science ®Google Scholar
• CarrothersTJ, ChittendenJT, CritchleyI. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2020;9(1):21–31. doi:10.1002/cpdd.69531087630
   PubMed Web of Science ®Google Scholar
• JonesRN, StilwellMG, SaderHS, FritscheTR, GoldsteinBP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States surveillance program (2004). Diagn Microbiol Infect Dis. 2006;54(2):149–153. doi:10.1016/j.diagmicrobio.2005.08.01516426793
   PubMed Web of Science ®Google Scholar
• PfallerMA, FlammRK, CastanheiraM, SaderHS, MendesRE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). Int J Antimicrob Agents. 2018;51(4):608–611. doi:10.1016/j.ijantimicag.2017.12.01129277526
   PubMed Web of Science ®Google Scholar
• BuckwalterM, DowellJA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279–1287. doi:10.1177/009127000528037816239361
   PubMed Web of Science ®Google Scholar
• AndesD, CraigWA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633–1642. doi:10.1128/AAC.01264-0617307987
   PubMed Web of Science ®Google Scholar
• LepakA, MarchilloK, VanHeckerJ, AndesD. Impact of glycopeptide resistance in staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother. 2015;59(12):7833–7836. doi:10.1128/AAC.01717-1526392492
   PubMed Web of Science ®Google Scholar
• MarburyT, DowellJA, SeltzerE, BuckwalterM. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465–476. doi:10.1177/009127000833016219318696
   PubMed Web of Science ®Google Scholar
• Van MatreET, TeitelbaumI, KiserTH. Intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients. Antimicrob Agents Chemother. 2020;64(5). doi:10.1128/AAC.02089-19
   Web of Science ®Google Scholar
• CoronaA, AgarossiA, VeroneseA, CattaneoD, D’AvolioA. Therapeutic drug monitoring of dalbavancin treatment in severe necrotizing fasciitis in 3 critically ill patients: a grand round. Ther Drug Monit. 2020;42(2):165–168. doi:10.1097/FTD.000000000000072932195987
   PubMed Web of Science ®Google Scholar
• Di PilatoV, CeccheriniF, SennatiS, et al. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. Diagn Microbiol Infect Dis. 2020;96(2):114901. doi:10.1016/j.diagmicrobio.2019.11490131761480
   PubMed Web of Science ®Google Scholar
• FernándezJ, Greenwood-QuaintanceKE, PatelR. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016;85(4):449–451. doi:10.1016/j.diagmicrobio.2016.05.00927241369
   PubMed Web of Science ®Google Scholar
• NeudorferK, Schmidt-MalanSM, PatelR. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn Microbiol Infect Dis. 2018;90(1):58–63. doi:10.1016/j.diagmicrobio.2017.09.01529195766
   PubMed Web of Science ®Google Scholar
• NicolauDP, SunHK, SeltzerE, BuckwalterM, DowellJA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60(3):681–684. doi:10.1093/jac/dkm26317631507
   PubMed Web of Science ®Google Scholar
• RappoU, DunneMW, PuttaguntaS, et al. Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1500-milligram infusion. Antimicrob Agents Chemother. 2019;63(11). doi:10.1128/AAC.01024-19
   Web of Science ®Google Scholar
• CojuttiPG, RinaldiM, ZampariniE, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021. doi:10.1128/AAC.02260-20
   Web of Science ®Google Scholar
• RappoU, PuttaguntaS, ShevchenkoV, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6(1):ofy331. doi:10.1093/ofid/ofy33130648126
   PubMed Web of Science ®Google Scholar
• RaadI, DarouicheR, VazquezJ, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374–380. doi:10.1086/42728315668859
   PubMed Web of Science ®Google Scholar
• VeveMP, PatelN, SmithZA, YeagerSD, WrightLR, ShormanMA. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. Int J Antimicrob Agents. 2020;56(6):106210. doi:10.1016/j.ijantimicag.2020.10621033223119
   PubMed Web of Science ®Google Scholar
• Hidalgo-TenorioC, VinuesaD, PlataA, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30. doi:10.1186/s12941-019-0329-631629409
   PubMed Web of Science ®Google Scholar
• TobudicS, ForstnerC, BurgmannH, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. Clin Infect Dis. 2018;67(5):795–798. doi:10.1093/cid/ciy27929659732
   PubMed Web of Science ®Google Scholar
• WunschS, KrauseR, ValentinT, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–214. doi:10.1016/j.ijid.2019.02.01330794940
   PubMed Web of Science ®Google Scholar
• DinhA, DuranC, PaveseP, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54(5):668–672. doi:10.1016/j.ijantimicag.2019.08.00631400471
   PubMed Web of Science ®Google Scholar
• Bryson-CahnC, BeielerAM, ChanJD, HarringtonRD, DhanireddyS. Dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019;6(2):ofz028. doi:10.1093/ofid/ofz02830838225
   PubMed Web of Science ®Google Scholar
• Vazquez DeidaAA, ShihadehKC, PreslaskiCR, YoungHL, WylesDL, JenkinsTC. Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy. Open Forum Infect Dis. 2020;7(8):ofaa293. doi:10.1093/ofid/ofaa29332793767
   PubMed Web of Science ®Google Scholar
• BouzaE, ValerioM, SorianoA, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571–577. doi:10.1016/j.ijantimicag.2017.11.00829180276
   PubMed Web of Science ®Google Scholar
• BaiF, AldieriC, CattelanA, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020;18(12):1271–1279. doi:10.1080/14787210.2020.179822732797758
   PubMed Web of Science ®Google Scholar
• AjakaL, HeilE, SchmalzleS. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel). 2020;9(10). doi:10.3390/antibiotics9100700
   Web of Science ®Google Scholar
• Núñez-NúñezMP, Casas-HidalgoI, García-FumeroR, et al. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm. 2020;27(5):310–312. doi:10.1136/ejhpharm-2018-00171132839266
   PubMedGoogle Scholar
• BorkJT, HeilEL, BerryS, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8(2):171–184. doi:10.1007/s40121-019-0247-031054088
   PubMed Web of Science ®Google Scholar
• SpazianteM, FranchiC, TalianiG, et al. Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. Open Forum Infect Dis. 2019;6(11):ofz427. doi:10.1093/ofid/ofz42731737736
   PubMed Web of Science ®Google Scholar
• HakimA, BraunH, ThorntonD, StrymishJ. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–205. doi:10.1016/j.ijid.2019.12.00831841726
   PubMed Web of Science ®Google Scholar
• SteeleJM, SeaburyRW, HaleCM, MogleBT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018;43(1):101–103. doi:10.1111/jcpt.1258028628223
   PubMed Web of Science ®Google Scholar
• KussmannM, KarerM, ObermuellerM, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7(1):202. doi:10.1038/s41426-018-0205-z30514923
   PubMed Web of Science ®Google Scholar
• HitzenbichlerF, MohrA, CamboniD, SimonM, SalzbergerB, HansesF. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection. 2021;49(1):181–186. doi:10.1007/s15010-020-01526-032965641
   PubMed Web of Science ®Google Scholar
• JonesBM, KeedyC, WynnM. Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis. 2018;76:4–5. doi:10.1016/j.ijid.2018.07.01630053580
   PubMed Web of Science ®Google Scholar
• ChoJC, EstradaSJ, BeltranAJ, RevueltaMP. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther. 2015;40(5):604–606. doi:10.1111/jcpt.1230626183753
   PubMed Web of Science ®Google Scholar
• WerthBJ, JainR, HahnA, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24(4):429.e1–429.e5. doi:10.1016/j.cmi.2017.07.028
   Web of Science ®Google Scholar
• CicculloA, GiulianoG, SegalaFV, TaddeiE, FarinacciD, PallaviciniF. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection. 2020;48(2):309–310. doi:10.1007/s15010-019-01379-231784895
   PubMed Web of Science ®Google Scholar
• Howard-AndersonJ, PouchSM, SextonME, et al. Left ventricular assist device infections and the potential role for dalbavancin: a case report. Open Forum Infect Dis. 2019;6(9):ofz235. doi:10.1093/ofid/ofz23531660392
   PubMed Web of Science ®Google Scholar
• Martínez-SanzJ, Gijón de la SantaL, TorralbaM. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator. Enferm Infecc Microbiol Clin. 2018;36(6):389–390. doi:10.1016/j.eimc.2017.10.002
   Web of Science ®Google Scholar
• TobudicS, ForstnerC, BurgmannH, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47(6):1013–1020. doi:10.1007/s15010-019-01354-x31520397
   PubMed Web of Science ®Google Scholar
• MorataL, CoboJ, Fernández-SampedroM, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5). doi:10.1128/AAC.02280-18
   PubMed Web of Science ®Google Scholar
• AlmangourTA, PerryGK, TerriffCM, AlhifanyAA, KayeKS. Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93(3):213–218. doi:10.1016/j.diagmicrobio.2018.10.00730396697
   PubMed Web of Science ®Google Scholar
• AlmangourTA, PerryGK, AlhifanyAA. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study. Saudi Pharm J. 2020;28(4):460–464. doi:10.1016/j.jsps.2020.02.00732273805
   PubMed Web of Science ®Google Scholar
• Buzón MartínL, Mora FernándezM, Perales RuizJM, et al. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study. Rev Esp Quimioter. 2019;32(6):532–538.31642637
   PubMed Web of Science ®Google Scholar
• AzamgarhiT, DonaldsonJ, ShahA, WarrenS. Dalbavancin to treat infected massive endoprostheses: a case report and cost comparison analysis. J Bone Jt Infect. 2019;4(5):234–237. doi:10.7150/jbji.3798031700772
   PubMedGoogle Scholar
• LoupaCV, LykoudiE, MeimetiE, et al. Successful treatment of diabetic foot osteomyelitis with dalbavancin. Med Arch. 2020;74(3):243–245. doi:10.5455/medarh.2020.74.243-24532801445
   PubMedGoogle Scholar
• Carrión MadroñalIM, Sánchez Del MoralR, Abad ZamoraJM, Martínez MarcosFJ. Dalbavancin combined with linezolid in prosthetic-hip infection. Rev Esp Quimioter. 2020;33(2):147–148. doi:10.37201/req/087.201932157859
   PubMed Web of Science ®Google Scholar
• Vates R, Rodríguez SJ, Martínez ME, Martínez JA. Experiencia clínica sobre un caso de osteomielitis tratado con dalbavancina [Clinical experience on a case of osteomyelitis treated with dalbavancin]. Rev Esp Quimioter. 2018. Spanish. Epub ahead of print. 
   Google Scholar
• AlmangourTA, FletcherV, AlessaM, AlhifanyAA, TabbD. Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant staphylococcus aureus: a case report. Am J Case Rep. 2017;18:1315–1319. doi:10.12659/ajcr.90593029222405
   PubMed Web of Science ®Google Scholar
• Molina ColladaJ, Rico NietoA, Díaz de Bustamante UssiaM, Balsa CriadoA. Septic arthritis in a native knee due to Corynebacterium striatum. Reumatol Clin. 2018;14(5):301–302. doi:10.1016/j.reuma.2017.01.01328283311
   PubMed Web of Science ®Google Scholar
• Trujillano Ruiz A, Mesquida Riera J, Serrano Fabiá MA, Riera Pérez E, Mejía Benard A, Taberner Ferrer MD. Tratamiento prolongado con dalbavancina en infección protésica de cadera por Staphylocuccus epidermidis resistente a meticilina [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis]. Rev Esp Quimioter. 2019;32(2):203–204. Spanish. Epub 2019 Mar 13.
   Google Scholar
• Barbero AllendeJM, García SánchezM, Culebras LópezAM, Agudo AlonsoR. Suppressive antibiotic treatment with dalbavancin. A case report. Rev Esp Quimioter. 2021;34(2):151–153. doi:10.37201/req/105.202033491409
   PubMed Web of Science ®Google Scholar
• Ramírez HidalgoM, Jover-SáenzA, García-GonzálezM, Barcenilla-GaiteF. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis. Enferm Infecc Microbiol Clin. 2018;36(2):142–143. doi:10.1016/j.eimc.2017.04.009
   Web of Science ®Google Scholar
• Álvarez OteroJ, Sanjurjo RivoA, Lamas FerreiroJL, de la Fuente AguadoJ. Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report. Rev Esp Quimioter. 2019;32(3):276–277.31037932
   PubMed Web of Science ®Google Scholar
• BartolettiM, MikusE, PascaleR, et al. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Resist. 2019;18:195–198. doi:10.1016/j.jgar.2019.03.01530926464
   PubMed Web of Science ®Google Scholar
• BarberKE, TirmiziA, FinleyR, StoverKR. Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia. J Pharmacol Pharmacother. 2017;8(2):77–79. doi:10.4103/jpp.JPP_2_1728706403
   PubMed Web of Science ®Google Scholar
• GuzekA, SuwalskiG, TomaszewskiD, RybickiZ. Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report. J Cardiothorac Surg. 2018;13(1):3. doi:10.1186/s13019-017-0690-529304832
   PubMed Web of Science ®Google Scholar
• StreifelAC, SikkaMK, BowenCD, LewisJS. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54(5):652–654. doi:10.1016/j.ijantimicag.2019.08.00731398481
   PubMed Web of Science ®Google Scholar
• BookstaverPB, MilgromA. Stewarding the costly antibiotic: considerations for dalbavancin. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1730
   Web of Science ®Google Scholar
• PolisenoM, BavaroDF, BrindicciG, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections. Clin Drug Investig. 2021;41:437–448. doi:10.1007/s40261-021-01028-3
   PubMed Web of Science ®Google Scholar
• WilkeM, WorfK, PreisendörferB, HeinleinW, KastT, BodmannK-F. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data. GMS Infect Dis. 2019;7:Doc03. doi:10.3205/id00004331728264
   PubMedGoogle Scholar
• MorrisetteT, MillerMA, MontagueBT, BarberGR, McQueenRB, KrsakM. Long-acting lipoglycopeptides: “lineless antibiotics” for serious infections in persons who use drugs. Open Forum Infect Dis. 2019;6(7):ofz274. doi:10.1093/ofid/ofz27431281868
   PubMed Web of Science ®Google Scholar
• AgarwalR, BartschSM, KellyBJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361–368. doi:10.1016/j.cmi.2017.08.02828882727
   PubMed Web of Science ®Google Scholar
• McCarthyMW, KeylounKR, GillardP, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther. 2020;9(1):53–67. doi:10.1007/s40121-019-00275-431713130
   PubMed Web of Science ®Google Scholar
• RappoU, GonzalezPL, PuttaguntaS, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60–65. doi:10.1016/j.jgar.2019.02.00730797084
   PubMed Web of Science ®Google Scholar
• SimonettiO, RizzettoG, MolinelliE, CirioniO, OffidaniA. Review: a safety profile of dalbavancin for on- and off-label utilization. Ther Clin Risk Manag. 2021;17:223–232. doi:10.2147/TCRM.S27144533790563
   PubMed Web of Science ®Google Scholar
• DunneMW, TalbotGH, BoucherHW, WilcoxM, PuttaguntaS. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39(2):147–157. doi:10.1007/s40264-015-0374-926715497
   PubMed Web of Science ®Google Scholar
• WangY, WangJ, WangR, LiY, CaiY. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections. J Glob Antimicrob Resist. 2021;24:72–80. doi:10.1016/j.jgar.2020.11.01833279683
   PubMed Web of Science ®Google Scholar
• BradleyJS, PuttaguntaS, RubinoCM, BlumerJL, DunneM, SullivanJE. Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12–17 years of age. Pediatr Infect Dis J. 2015;34(7):748–752. doi:10.1097/INF.000000000000064625551831
   PubMed Web of Science ®Google Scholar
• GonzalezD, BradleyJS, BlumerJ, et al. Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age. Pediatr Infect Dis J. 2017;36(7):645–653. doi:10.1097/INF.000000000000153828060045
   PubMed Web of Science ®Google Scholar
• DunneMW, ZhouM, DarpoB. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393–398. doi:10.1016/j.ijantimicag.2014.12.02125681068
   PubMed Web of Science ®Google Scholar
• MahoneyMV, PadivalS. Receipt of supratherapeutic dalbavancin. Am J Health Syst Pharm. 2020;77(5):326–328. doi:10.1093/ajhp/zxz33731950151
   PubMed Web of Science ®Google Scholar
• Abdul-MutakabbirJC, KebriaeiR, StamperKC, et al. Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antibiotics (Basel). 2020;9(10). doi:10.3390/antibiotics9100696
   Web of Science ®Google Scholar
• KebriaeiR, RiceSA, StamperKC, RybakMJ. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.01743-18
   Web of Science ®Google Scholar
• AktasG, DerbentliS. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. J Antimicrob Chemother. 2017;72(2):441–443. doi:10.1093/jac/dkw41628073963
   PubMed Web of Science ®Google Scholar
• BaldoniD, Furustrand TafinU, AeppliS, et al. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Int J Antimicrob Agents. 2013;42(3):220–225. doi:10.1016/j.ijantimicag.2013.05.01923880168
   PubMed Web of Science ®Google Scholar